|
|
Blood, 1 May 2004, Vol. 103, No. 9, pp. 3503-3510.
Prepublished online as a Blood First Edition Paper on December 11, 2003; DOI 10.1182/blood-2003-07-2340.
 Previous Article | Table of Contents | Next Article 
NEOPLASIA
Involvement of Notch-1 signaling in bone marrow stroma-mediated de novo drug resistance of myeloma and other malignant lymphoid cell lines
Yulia Nefedova,
Pingyan Cheng,
Melissa Alsina,
William S. Dalton, and
Dmitry I. Gabrilovich
From the H Lee Moffitt Cancer Center and Research Institute, University of South Florida, Tampa, FL.
The bone marrow (BM) microenvironment plays a critical role in malignant cell growth, patient survival, and response to chemotherapy in hematologic malignancies. However, mechanisms associated with this environmental influence remain unclear. In this study, we investigated the role of Notch family proteins in myeloma and other malignant lymphoid cell line growth and response to chemotherapeutic drugs. All 8 tested cell lines expressed Notch-3 and Notch-4; 7 cell lines expressed Notch-1; and 6 expressed Notch-2 proteins. Interaction with BM stroma (BMS) activated Notch signaling in tumor cells. However, activation of only Notch-1, but not Notch-2, resulted in protection of tumor cells from melphalan- and mitoxantrone-induced apoptosis. This protection was associated with up-regulation of p21WAF/Cip and growth inhibition of cells. Overexpression of Notch-1 in Notch-1- U266 myeloma cells up-regulated p21 and resulted in protection from drug-induced apoptosis. Thus, this is a first report demonstrating that Notch-1 signaling may be a primary mechanism mediating the BMS influence on hematologic malignant cell growth and survival. (Blood. 2004; 103:3503-3510)
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
Related Article in Blood Online:
-
Notch signaling: a key to the pathogenesis of multiple myeloma?
- Laurie A. Milner
Blood 2004 103: 3253-3254.
[Full Text]
[PDF]
This article has been cited by other articles:
|
|
|
|
 
P. Ghoshal, A. J. Nganga, J. Moran-Giuati, A. Szafranek, T. R. Johnson, A. J. Bigelow, C. M. Houde, H. Avet-Loiseau, D. J. Smiraglia, N. Ersing, et al.
Loss of the SMRT/NCoR2 Corepressor Correlates with JAG2 Overexpression in Multiple Myeloma
Cancer Res.,
May 15, 2009;
69(10):
4380 - 4387.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Rosati, R. Sabatini, G. Rampino, A. Tabilio, M. Di Ianni, K. Fettucciari, A. Bartoli, S. Coaccioli, I. Screpanti, and P. Marconi
Constitutively activated Notch signaling is involved in survival and apoptosis resistance of B-CLL cells
Blood,
January 22, 2009;
113(4):
856 - 865.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. D. Meng, C. C. Shelton, Y.-M. Li, L.-X. Qin, D. Notterman, P. B. Paty, and G. K. Schwartz
{gamma}-Secretase Inhibitors Abrogate Oxaliplatin-Induced Activation of the Notch-1 Signaling Pathway in Colon Cancer Cells Resulting in Enhanced Chemosensitivity
Cancer Res.,
January 15, 2009;
69(2):
573 - 582.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. B. Meads, L. A. Hazlehurst, and W. S. Dalton
The Bone Marrow Microenvironment as a Tumor Sanctuary and Contributor to Drug Resistance
Clin. Cancer Res.,
May 1, 2008;
14(9):
2519 - 2526.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Nefedova, D. M. Sullivan, S. C. Bolick, W. S. Dalton, and D. I. Gabrilovich
Inhibition of Notch signaling induces apoptosis of myeloma cells and enhances sensitivity to chemotherapy
Blood,
February 15, 2008;
111(4):
2220 - 2229.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Neri, S. Kumar, M. T. Fulciniti, S. Vallet, S. Chhetri, S. Mukherjee, Y. Tai, D. Chauhan, P. Tassone, S. Venuta, et al.
Neutralizing B-Cell Activating Factor Antibody Improves Survival and Inhibits Osteoclastogenesis in a Severe Combined Immunodeficient Human Multiple Myeloma Model
Clin. Cancer Res.,
October 1, 2007;
13(19):
5903 - 5909.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Lwin, L. A. Hazlehurst, S. Dessureault, R. Lai, W. Bai, E. Sotomayor, L. C. Moscinski, W. S. Dalton, and J. Tao
Cell adhesion induces p27Kip1-associated cell-cycle arrest through down-regulation of the SCFSkp2 ubiquitin ligase pathway in mantle-cell and other non-Hodgkin B-cell lymphomas
Blood,
September 1, 2007;
110(5):
1631 - 1638.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. S. Huang, S. Duan, W. K. Bleibel, E. O. Kistner, W. Zhang, T. A. Clark, T. X. Chen, A. C. Schweitzer, J. E. Blume, N. J. Cox, et al.
A genome-wide approach to identify genetic variants that contribute to etoposide-induced cytotoxicity
PNAS,
June 5, 2007;
104(23):
9758 - 9763.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. Bolos, J. Grego-Bessa, and J. L. de la Pompa
Notch Signaling in Development and Cancer
Endocr. Rev.,
May 1, 2007;
28(3):
339 - 363.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Tabe, L. Jin, Y. Tsutsumi-Ishii, Y. Xu, T. McQueen, W. Priebe, G. B. Mills, A. Ohsaka, I. Nagaoka, M. Andreeff, et al.
Activation of Integrin-Linked Kinase Is a Critical Prosurvival Pathway Induced in Leukemic Cells by Bone Marrow-Derived Stromal Cells
Cancer Res.,
January 15, 2007;
67(2):
684 - 694.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Cheng, Y. Nefedova, C. A. Corzo, and D. I. Gabrilovich
Regulation of dendritic-cell differentiation by bone marrow stroma via different Notch ligands
Blood,
January 15, 2007;
109(2):
507 - 515.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. Dalton and K. C. Anderson
Synopsis of a Roundtable on Validating Novel Therapeutics for Multiple Myeloma.
Clin. Cancer Res.,
November 15, 2006;
12(22):
6603 - 6610.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y.-M. Zhu, W.-L. Zhao, J.-F. Fu, J.-Y. Shi, Q. Pan, J. Hu, X.-D. Gao, B. Chen, J.-M. Li, S.-M. Xiong, et al.
NOTCH1 Mutations in T-Cell Acute Lymphoblastic Leukemia: Prognostic Significance and Implication in Multifactorial Leukemogenesis.
Clin. Cancer Res.,
May 15, 2006;
12(10):
3043 - 3049.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. G. Leong and A. Karsan
Recent insights into the role of Notch signaling in tumorigenesis
Blood,
March 15, 2006;
107(6):
2223 - 2233.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Miele
Notch Signaling
Clin. Cancer Res.,
February 15, 2006;
12(4):
1074 - 1079.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Stylianou, R. B. Clarke, and K. Brennan
Aberrant Activation of Notch Signaling in Human Breast Cancer
Cancer Res.,
February 1, 2006;
66(3):
1517 - 1525.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. A. Zweidler-McKay, Y. He, L. Xu, C. G. Rodriguez, F. G. Karnell, A. C. Carpenter, J. C. Aster, D. Allman, and W. S. Pear
Notch signaling is a potent inducer of growth arrest and apoptosis in a wide range of B-cell malignancies
Blood,
December 1, 2005;
106(12):
3898 - 3906.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Quesnel
Multiple myeloma: all roads lead to cyclin D
Blood,
July 1, 2005;
106(1):
1 - 2.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. A. Jungbluth, S. Ely, M. DiLiberto, R. Niesvizky, B. Williamson, D. Frosina, Y.-T. Chen, N. Bhardwaj, S. Chen-Kiang, L. J. Old, et al.
The cancer-testis antigens CT7 (MAGE-C1) and MAGE-A3/6 are commonly expressed in multiple myeloma and correlate with plasma-cell proliferation
Blood,
July 1, 2005;
106(1):
167 - 174.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Takeuchi, Y. Adachi, and Y. Ohtsuki
Skeletrophin, a Novel Ubiquitin Ligase to the Intracellular Region of Jagged-2, Is Aberrantly Expressed in Multiple Myeloma
Am. J. Pathol.,
June 1, 2005;
166(6):
1817 - 1826.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Yin
Chondroitin Synthase 1 Is a Key Molecule in Myeloma Cell-Osteoclast Interactions
J. Biol. Chem.,
April 22, 2005;
280(16):
15666 - 15672.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Matsumoto and M. Abe
The Importance of Notch Signaling in Myeloma Cell-Osteoclast Interactions
IBMS BoneKEy,
February 1, 2005;
2(2):
7 - 10.
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Houde, Y. Li, L. Song, K. Barton, Q. Zhang, J. Godwin, S. Nand, A. Toor, S. Alkan, N. V. Smadja, et al.
Overexpression of the NOTCH ligand JAG2 in malignant plasma cells from multiple myeloma patients and cell lines
Blood,
December 1, 2004;
104(12):
3697 - 3704.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
